Confessions of a Data Quality Manager
|
|
- Clarence Edwards
- 5 years ago
- Views:
Transcription
1 Confessions of a Data Quality Manager FCDS Annual Conference Boca Raton, Florida 7/28/2016 Steven Peace, CTR
2 Outline 20 Data Quality Issues in 45 Minutes
3 Reference Dates & Accession Numbers FCDS Reference Date & FCDS Acc # 01/01/1981 FCDS Reference Date FCDS Reference Date Never Changes CoC Reference Date & Facility Acc # 1930-Today - CoC Reference Date CoC Reference Date Can Be Changed FCDS has cases from your facility going back to 01/01/1981 admissions FCDS Facility/Accession # FCDS Facility/Accession Never Changes even if you scrap your facility database or change your CoC Reference Date Your Facility/Accession # Must Match the FCDS Facility Accession # of old Facility Reference Date for FCDS 01/01/1981 Hospitals 07/01/1997 Ambi Dx/Tx Centers 07/01/1997 Pathology Labs Your Facility/Accession # Must Match the Original (old) FCDS Facility Accession # Only the Sequence # Changes
4 RQRS Case Reported to FCDS When to Send Abstract to FCDS Transmit Data at Least Quarterly Facilities Reporting >500 Cases SHOULD Transmit Data Monthly DO NOT SEND INCOMPLETE (Active) RQRS CASES TO FCDS Send Case to FCDS when; All First Course Therapy Completed Six Month Reporting Requirement FCDS Annual Deadline FCDS Has No Update Abstract Tool Cases sent to FCDS without all first course therapy do not have another opportunity to get updated from your facility. Any additional first course treatment never will get to FCDS and the case looks incomplete. Any other critical case updates will never get to FCDS, either.
5 Text Requirements Apply to ALL Cases You must ensure that all coded values are supported by text Overuse and Misuse of Abbreviations is Worse than Ever and is being Monitored TAKE YOU TIME & BE CAUTIOUS! ALWAYS cancer description at first presentation, symptoms, cancer(s) history, why was patient at the facility ALWAYS description of patient - 75yr old Cuban male, 64 yr old black female, 49 yr old Haitian male ALWAYS Dates of lab tests, scans and imaging studies, oscopy, biopsy, surgery, staging, pathology for all tissue examined, and ALL treatment Goal: a full chronology of care from diagnosis to present ALWAYS Include Positive and Negative findings from surgery, imaging, staging procedures, pathology, clinical exam
6 Class of Case 32 and Text Requirements You must provide a chronology of care diagnosis to current ALWAYS INCLUDE cancer description at first presentation, symptoms, cancer(s) history, why was patient at the facility ALWAYS INCLUDE description of patient - 75yr old Cuban male, 64 yr old black female, 49 yr old Haitian male ALWAYS INCLUDE Dates of lab tests, scans and imaging studies, oscopy, biopsy, surgery, staging, pathology for all tissue examined, and ALL treatment.
7 Non-Analytic Case First Course Tx Elsewhere Still need to document and code all first course treatment (including active surveillance) as well as complete staging even when your facility was not involved in the original dx or tx or when all your facility does is diagnose the cancer. This includes treatment for palliation-only. Palliative chemo, surgery, and radiation are still cancer treatment, even if not intended to cure. If it is first course document it and code it. CoC may not require that you complete information on Non- Analytic Cases but FCDS does require complete text and tx.
8 Patient Demographics Even Require Text Transposed First and Last Name Hispanic and Multiple Surname Sex Coding Errors Sex - Reproductive Cancers Sex - Non-Reproductive Cancers Sex - Gender Identity & Transition Sex - Unusual first names Errors Still Increasing - Over 5 Years Registrars still not checking Use Name Check Validation Edit Failures will be validated Edit Failures need Force
9 Date of Diagnosis: By Imaging or Pathology?
10 Is it really an unknown primary? Why? C80.9 or C76.* as Seq 01-Historical C80.9 & History of Other Cancer(s)
11 Epidemic of NOS and Ill-Defined Codes Use Registrars coding NOS frequently for some reason This Not Acceptable Especially on Analytic Cases Document AND Code the Most Specific Available Increases in Unknown Primary & Ill-Defined Site Primary Site, NOS when subsite is known Histology, NOS when specific subtype is known Increases in Unknown Stage and Unknown Biomarkers Surgery, NOS codes of 80, 90 are meaningless Radiation, NOS Chemo, NOS
12 Correct Use of 2014 Grade Coding Instructions
13 # Nodes Examined & # Nodes Positive 98/00 or 00/98 they are different 00 = Nodes Examined 98 = Nodes Positive They are different!! Coding 99/99 when no surgery done If no surgery performed 00 = Nodes Examined 98 = Nodes Positive How are these different?
14 Where is Your Decimal Point? Tumor Size (XXXmm) Depth of Invasion (X.XXmm) PSA (XX.Xng/ml) Depth of Invasion Melanoma Prostate PSA Value (XX.X ng/ml) SSF Code Depth Invasion Units mm mm mm mm mm SSF Code PSA Value Units ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml
15 Coding Surgery Fields Correctly Surgery of Primary Site Surg, NOS Surgery of Other, Regional, Distant Was tissue removed en bloc with primary site or regional surgery? Was the removal incidental? Was the removal to remove cancerous tissue? Was the removal a debulking? Do not double-code the surgery Do not code surgery if not to remove suspected cancerous tissue or known cancerous tissue
16 Coding Anti-Neoplastic Agents SEER*Rx Chemo Regimens List All Agents If you do not know which drugs are included look it up!!! Many protocols mix multiple classes of agents such as chemo, hormones, and immunotherapy Some protocols include drugs/ agents plus other types of therapy such as radiation or BMT COG-A3973 is not good enough BRM/Immunotherapy Critical Class Do Not Guess by Name of Agent Rituximab - Trastuzumab Herceptin - Bevacizumab Revlimid - Panitumumab Crizotinib - Pertuzumab Alectinib - Ipilimumab Ceritinib - Keytruda BCG - Darzalex Levamisole - Lenalidomide
17 Coding New Radiation Delivery Methods New Intra-Operative Radiotherapy Intrabeam IORT MammoSite - TARGIT All are brachytherapy modality Target Dose often single dose Can be high-dose or low-dose Low dose as low as 50 kv High dose as much as 2000cGy Treatment to primary tumor bed Place balloon catheter or Place 1 or a few Targets in bed Glass or Gold Bead(s) are Target Target absorbs the radiation
18 Talk about Miniature Sample x-ray Sources and tcr.amegroups.com
19 Questions Work in his Future Office
FCDS Text and Documentation Requirements: A Key Component to Providing High Quality Data
FCDS Text and Documentation Requirements: A Key Component to Providing High Quality Data 2011 FCDS Educational Webcast Series Mayra Espino, BA, RHIT, CTR Steven Peace, BS, CTR August 18, 2011 CDC-NPCR
More informationAJCC TNM STAGING UPDATES ARE YOU READY FOR TNM?
AJCC TNM STAGING UPDATES ARE YOU READY FOR TNM? FCRA Annual Conference Boca Raton, Florida 7/26/2016 Steven Peace, CTR 1 Introduction Order AJCC Cancer Staging Manual, 7 th ed. How To Use - AJCC Cancer
More informationRequirements for Abstracted Text
Slide 1 Requirements for Abstracted Text Principles of Abstracting Lesson 3: Purpose of Text Slide 2 Available Text Fields Place of Diagnosis Immunotherapy Chemotherapy Hormone Therapy Other Therapy Radiation
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationFCDS Annual Educational Conference Orlando, Florida July 28, Steven Peace, CTR
FCDS Annual Educational Conference Orlando, Florida July 28, 2017 Steven Peace, CTR 1 Outline 2018 Transition from CS SSFs to Individual Site Specific Prognostic Factor Fields (SSFs) Locating SSFs in the
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationClick here to register! WHAT S NEW: For more information contact:
MAY-JUNE 14 WHAT S NEW: The following information is currently available on the FCDS website. For more information contact: Bleu Thompson Florida Cancer Data System PO Box 016960 (D4-11) Miami, Florida
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationCERVIX MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) CERVIX MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve
More informationNCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS
NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate
More informationInteractive Discussion of Part I CS Coding Instructions: Working the Cases
Interactive Discussion of Part I CS Coding Instructions: Working the Cases April Fritz, RHIT, CTR Donna M. Gress, RHIT, CTR Jennifer Ruhl, RHIT, CCS, CTR This presentation was supported by the Cooperative
More informationI.2 CNExT This section was software specific and deleted in 2008.
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
More informationNCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA /9/17 Eileen Tonner, MS
NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA 2017-044 5/9/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate
More informationOutline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.
1 How to Use the AJCC Cancer Staging Manual, 7 th ed. FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015 Steven Peace, CTR Outline 2 History, Purpose and Background Purchase and Ordering Information
More informationNCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions
NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without
More informationCommission on Cancer Updates
Commission on Cancer Updates OBJECTIVES PROVIDE CANCER REGISTRARS WITH INFORMATION ABOUT CURRENT COC 2018 CHANGES DISCUSS CHANGES RELATED TO CANCER REGISTRY DATA COLLECTION DISCUSS CHANGES RELATED TO CANCER
More informationCDC & Florida DOH Attribution
FCDS Annual Educational Conference Tampa, Florida July 19, 2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution Funding for this conference was made possible (in part) by the Centers for Disease Control
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationComplete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting
Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting Eric B. Durbin, DrPH, MS, Director of Cancer Informatics Frances E. Ross, CTR,
More informationCDC & Florida DOH Attribution
FCDS Annual Educational Conference Tampa, Florida July 19, 2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution We acknowledge the Centers for Disease Control and Prevention, for its support of the Florida
More informationData Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data,
Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data, 2004-2012 Jeanne Whitlock, MSLS, CTR Julie George, MS Ron Shore, MPH Fawn D. Vigneau, JD, MPH Metropolitan
More informationGary M. Levin, BA, CTR FCDS Annual Conference 7/26/2017
Gary M. Levin, BA, CTR FCDS Annual Conference 7/26/2017 Presentation Overview Background Methods Results Conclusions 2 1 Background Increase physician reporting Capture missing first course treatment Capture
More informationCDC & Florida DOH Attribution
SCCRA/GATRA Regional Conference North Charleston, SC 11/6/2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution Funding for this conference was made possible (in part) by the Centers for Disease Control
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
More informationEducation & Training Plan FCDS Webcast Series Anatomic Staging Focus
2015-2016 Education & Training Plan FCDS Webcast Series Anatomic Staging Focus 1 F C D S A N N U A L C O N F E R E N C E S T P E T E R S B U R G, F L O R I D A 7 / 2 9 / 2 0 1 5 S T E V E N P E A C E,
More informationBreast Conservation Therapy
May 18, 2018 Breast Conservation Therapy One Treatment No Longer Fits All Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. Define stages of breast cancer that are candidates
More informationColon, Rectum, and Appendix. Presentation Outline. Overview Tumor Characteristics
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More informationColon, Rectum, and Appendix
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More informationPart VIII Entering Information Into the Urology Report Form
North Carolina Central Cancer Registry Instructions and Reporting Requirements Module 8 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry State Center
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationNCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH
NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Project Overview Ronald C. Chen, MD MPH Introductions Principal Investigator: Ronald C. Chen, MD MPH ACS Staff: Eileen Tonner,
More informationEvaluation of Abstracting: Cancers Diagnosed in MCSS Quality Control Report 2005:2. Elaine N. Collins, M.A., R.H.I.A., C.T.R
Evaluation of Abstracting: Cancers Diagnosed in 2001 MCSS Quality Control Report 2005:2 Elaine N. Collins, M.A., R.H.I.A., C.T.R Jane E. Braun, M.S., C.T.R John Soler, M.P.H September 2005 Minnesota Department
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationEvaluation of Cancer Outcomes Barwon South West Registry
Evaluation of Cancer Outcomes Barwon South West Registry Data Request Form Applicant details Applicant name: Position: Email: Project start date: Date: Telephone: Project completion date: Project details
More informationNeoplasms of the Prostate and Bladder
Neoplasms of the Prostate and Bladder 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 CDC & Florida DOH Attribution
More informationCase Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
More informationGenitourinary Neoplasms Updated for 2012 Requirements and CSv02.04
Presentation Outline Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04 X:\FCDS_PUB\wwwroot\downloads\Teleconfere nces\2013 FCDS Educational Webcast Series February 28, 2013 General Information
More informationGenitourinary Neoplasms Updated for 2012 Requirements and CSv02.04
Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04 X:\FCDS_PUB\wwwroot\downloads\Teleconfere nces\2013 FCDS Educational Webcast Series February 28, 2013 1 Steven Peace, BS, CTR Susan Smith
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationGenitourinary. Presentation Outline. Genitourinary System 12/14/2011. FCDS 2011 Educational Webcast Series December 15, 2011
Genitourinary FCDS 2011 Educational Webcast Series December 15, 2011 1 Susan Smith Pierce, CTR Gema Midence, MBA, CTR Steven Peace, BS, CTR Presentation Outline Overview including Anatomy and General Information
More informationWeb Plus Instructions Radiation CCR
Web Plus Instructions Radiation CCR To begin entering Abstracts through Web Plus, you must first log into https://webplus.njscr.org/webplus/logonen.aspx with credentials that are provided to you once your
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationThe Components of an Abstract. Alfreda Woods, BS, CHES, CTR Program Manager, DCCR DelMarVa-DC Educational Conference October 12, 2018
The Components of an Abstract Alfreda Woods, BS, CHES, CTR Program Manager, DCCR DelMarVa-DC Educational Conference October 12, 2018 1 Abstracts Should Tell A Story 2 The Components of an Abstract Who
More informationMaking the Most of Your Cancer Registry
www.champsods.com Making the Most of Your Cancer Registry Presenter: Toni Hare, Vice President CHAMPS Oncology Data Services Picture of girl here December 11, 2009 Learning Objectives Upon completion of
More informationCollecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009
Collecting Cancer Data: Prostate NAACCR 2008-2009 Webinar Series June 11, 2009 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview 2008-2009 NAACCR Webinar Series
More informationWho What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC
Who What When Where Why Case Finding 5 W s NAACCR 2010-2011 Webinar Series Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC Agenda Case Finding Purpose Reportable lists Benign intracranial
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationEARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT
May 13, 2016 EARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. List treatment options for early stage breast cancer. 2.
More information10/24/2013. Continuing Education Hours. Presentation Outline. Rule Makers for National Data Collection. NPCR Program Standards,
2 013-2014 QUALITY IMPROVEMENT EDUCATION AND TRAINING NCRA CEU # 2013-114 Continuing Education Hours Date Event Sponsor 7/25/2013-7/26/2013 CEU Hrs FCDS Annual Conference, Sunrise, FL FCDS 8.25 2013-115
More informationPathology: Grade 1 infiltrating ductal carcinoma with associated DCIS, Lymphvascular invasion present. ER+, PR+. Her 2/ IHC 1+, negative
GATRA 2016 Breast Case Demographics Name: Autumn Leaf Sex: F Date of Birth: 3/26/75 SSN: 098765432 Race: African American Marital Status: Single Address: 3615 Burnt Hickory Trail, Helen, GA 37285, White
More informationOverview...3. Cancer Program.4. Breast Cancer with 5-year Survival Analysis...6. Systemic Therapy.7. Stage of Breast Cancer Diagnosed in
2011 Annual Report Table Of Contents Overview...3 Cancer Program.4 Breast Cancer with 5-year Survival Analysis...6 Systemic.7 Stage of Breast Cancer Diagnosed in 2008..8 Radiation and Systemic Only...9
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationNAACCR WEBINAR: ABSTRACTING THYROID/LARYNX CANCER INCIDENCE FLORIDA: PEDIATRIC CANCER ADMISSIONS (TOTAL), ANALYTIC CASES ONLY FCDS REGISTER VOL.
NAACCR WEBINAR: ABSTRACTING THYROID/LARYNX CANCER INCIDENCE AND TREATMENT DATA ON 3/6/2008. SESSION #5 OF 8 IS BEING HELD AT BOCA RATON COMMUNITY HOSPITAL, MOFFITT CANCER CENTER, AND SHANDS UNIVERSITY
More informationShore Medical Center Site-Specific Study: Colorectal Cancer 2013
Shore Medical Center Site-Specific Study: Colorectal Cancer Shore Medical Center Site-Specific Study: Colorectal Cancer The following report is the result of a collaborative effort of four physician members
More informationGREATER BALTIMORE MEDICAL CENTER SANDRA & MALCOLM BERMAN CANCER INSTITUTE
GREATER BALTIMORE MEDICAL CENTER SANDRA & MALCOLM BERMAN CANCER INSTITUTE CANCER REGISTRY REPORT The Cancer Data Management System/Cancer Registry collects data on all types of cancer diagnosed or treated
More informationFlorida Cancer Data System, University of Miami. Presentation for the Annual Conference of the North American Association of Central Cancer
Hernandez, MN, Mackinnon, JA, Fleming, LE, Lee, DJ Florida Cancer Data System, University of Miami Presentation for the Annual Conference of the North American Association of Central Cancer Registries
More informationACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationCausation Issues. Delay in Diagnosis of Cancer Cases. Prof Pat Price Imperial College London
Causation Issues Delay in Diagnosis of Cancer Cases Prof Pat Price Imperial College London office@patprice.co.uk www.patprice.co.uk Faculty of Advocates Annual conference 18 th June 2018 EVIDENCE BASED
More informationINITIAL SYSTEMIC TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER
INITIAL SYSTEMIC TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER Fran Maguire, MPH, PhD candidate California Cancer Reporting and Epidemiologic Surveillance (CalCARES) Program NAACCR Annual Conference
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More informationFORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute
FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute Charlotte, NC National Accreditation Program for Breast
More informationVivien W. Chen, PhD Mei-Chin Hsieh, MSPH, CTR Lisa A. Pareti, BS, CTR Xiao-Cheng Wu, MD, MPH, CTR. NAACCR Conference Portland, Oregon, June 5-7, 2012
Vivien W. Chen, PhD Mei-Chin Hsieh, MSPH, CTR Lisa A. Pareti, BS, CTR Xiao-Cheng Wu, MD, MPH, CTR NAACCR Conference Portland, Oregon, June 5-7, 2012 Background Purpose/Objective Methods Results Implications/Next
More informationGreater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute
2008 ANNUAL REPORT Greater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute Cancer Registry Report The Cancer Data Management System/ Cancer Registry collects data on all types of cancer
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationOne Stop Prostate Biopsy Protocol Author Consultation Date Approved
One Stop Prostate Biopsy Protocol Author Consultation Date Approved Urology Nurse Practioner PROTOCOL FOR MEN ATTENDING A ONE STOP PROSTATE BIOPSY CLINIC RATIONALE Prostate cancer is the most common cancer
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationOVARY MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) OVARY MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve the
More informationOncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
More informationPatient Identification Quiz
Patient Identification Quiz 1. A patient presents to your facility for the first time on 1/1/2009. At that time he has a history of lymphoma (9590/3), melanoma (8720/3) and meningioma (9530/0). These three
More informationInformational Abstracts: A Guide to Quality Abstracting
Informational Abstracts: A Guide to Quality Abstracting Presented by NCRA Education Committee Carole Eberle, BS, CTR Louise Schuman, MA, CTR NCRA Education Committee NCRA Strategic Planning and Education
More informationCollaborative Staging
Slide 1 Collaborative Staging Site-Specific Instructions Prostate 1 In this presentation, we are going to take a closer look at the collaborative staging data items for the prostate primary site. Because
More informationFaster Cancer Treatment Indicators: Use cases
Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationCS Tumor Size. We re on the Web! Visit us at www2.kumc.edu/kcr
VOLUME 17 ISSUE 3 July 2013 We re on the Web! Visit us at www2.kumc.edu/kcr July is UV Awareness Month. It is that time of the year again for summer! This is a great opportunity to talk about skin cancer.
More informationMCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR
MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationCongratulations to Florida CTRs Summer 2015
JANUARY 2016 Congratulations to Florida CTRs Summer 2015 Syrrona Goode Margate Joshua Johnson Fort Lauderdale Ismael Rodriguez Miami Cynthia Walls Coral Springs WHAT S NEW: The following information is
More informationKIDNEY MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) KIDE MEASURE SPECIFICATIOS Introduction The Commission on Cancer s (CoC) ational Cancer Data Base (CDB) staff has undertaken an effort to improve the transparency
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationRECTAL MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) RECTAL MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve
More informationMelanoma. Exceptional healthcare, personally delivered
Melanoma Exceptional healthcare, personally delivered What is Melanoma? Malignant Melanoma is a form of Skin Cancer which can start in a preexisting mole or normal looking skin. What causes Melanoma? Although
More informationThe procedures for the processing of FCDS IDEA User Accounts and FCDS Abstractor Codes has been revised.
MARCH 13 WHAT S NEW: The procedures for the processing of FCDS IDEA User Accounts and FCDS Abstractor Codes has been revised. Please review the following links and information for detailed instructions
More informationUNDERSTANDING SQUAMOUS CELL LUNG CANCER
UNDERSTANDING SQUAMOUS CELL LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure This brochure
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More informationCOLLABORATIVE STAGING - NEW VERSION (1.03) FCDS REGISTER VOL. 32
COLLABORATIVE STAGING - NEW VERSION (1.03) RELEASED 09-08-06 FCDS REGISTER VOL. 32 In response to questions and concerns raised by registrars about the FCDS implementation schedule of the recently released
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationCase Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationAccuracy of the SEER HPV status site specific factor 10 (SSF-10) variable for head and neck cancer (HNC) cases in Iowa:
Accuracy of the SEER HPV status site specific factor 10 (SSF-10) variable for head and neck cancer (HNC) cases in Iowa: 2010-2014 Amanda Kahl, MPH Mary Charlton, PhD, Nitin Pagedar, MD, MPH, Steven Sperry,
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More information7/29/ Education & Training Plan FCDS Webcast Series and VoIP Audio. Outline Education & Training Plan
2014-2015 Education & Training Plan FCDS Webcast Series and VoIP Audio 1 2 0 1 4-2 0 1 5 F C D S E D U C A T I O N & T R A I N I N G P L A N T R A I N I N G T O O L S A N D R E S O U R C E S G O T O M
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationLesson 8 Classifications
Lesson 8 Classifications Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers for Disease
More informationMAY 1, 2007 LETTER FROM RODNEY JOHNSON, DEPARTMENT PRIVACY OFFICER, FLORIDA DEPT. HEALTHCARE PRACTITIONER REPORTING GUIDELINES OF
MAY 1, 2007 LETTER FROM RODNEY JOHNSON, DEPARTMENT PRIVACY OFFICER, FLORIDA DEPT. OF HEALTH ON CANCER REPORTING TO FCDS HEALTHCARE PRACTITIONER REPORTING GUIDELINES OF NOTIFIABLE DISEASES OR CONDITIONS
More informationNAACCR Webinar 2018 SeriesImplementations and Timelines
NAACCR 2015-2016 Webinar 2018 SeriesImplementations and Timelines August 8, 2017 Session 1 Q&A Please submit all questions concerning webinar content through the Q&A panel. A recording of today s session,
More informationGeneral Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators
American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.
More information